The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
Now to the accounting boffins, should this be 2020 or 2021 revenue. If they have already paid £10 million where does that sit?
I just googled The value of NHS data. remember seeing the article in the paper last year.
Yes we all going to need the NHS at some stage. I have not but my 4 year old son has. There is so much valuable data held, and with the onward march to personalized medication the more data they better the treatment. Like you I have held since first dip in May last year. But am of the opinion that it will not have you specific information, but at X time we injected you with Vaccine Y within Z time period there was a slow increase in body Temp, pulse rate etc...Studies found if a day 3 your statistic went in A direction you have Covid but if the went in B direction you have influenza. These are the recommended treatments and actions you need. In hind sight with my son this would have saved 5 different 4 day stays in hospital it, would have saved white coats rushing him into isolation, me doing a mad dash to get to hospital etc. For the real time that wearable information would have been vital was when he was not sick and having hospital visits...So I believe we have to take bold forward steps while not only saving lives but also save wasted costs by proactive actions
As a society, we are finally acquiring a healthy scepticism about the use and abuse of our personal information. New polling conducted by YouGov for the Institute for Public Policy Research shows that 80% of the public want to see tighter rules applied to how the likes of Facebook and Amazon use their data. Over the weekend, it was revealed that US pharmaceutical companies have already been sold data relating to millions of NHS patients and that Amazon, incredibly, has been given free access to NHS data Hidden away in the secret US-UK trade papers, leaked and revealed by Labour in November, is perhaps the biggest single threat to public data yet seen.
Instead of the encroaching privatisation of publicly held data, we should be looking to create a “digital commons”
The potential threat to the NHS from a post-Brexit US trade deal is clear, and has become a major election talking point. But alongside the well-known dangers of accelerating privatisation and drug price hikes, there are risks to one of the UK’s most prized publicly owned resources. The NHS has one of the planet’s most valuable repositories of data: primary care records that cover sometimes decades of consistent, high-quality, trusted data on 55 million individuals, potentially covering their entire health histories. On top of that, an estimated 23 million care records document episodic treatments when patients receive secondary or specialist care. Accountants Ernst & Young estimate its value at £9.6bn annually.
Advertisement
For pharmaceutical companies, such comprehensive data is considerably more valuable than any sample. Large, clean, consistent and trusted datasets such as the NHS’s are a goldmine. Already, medical researchers are deriving useful results from machine-learning techniques – for instance, in providing rapid diagnoses of cataracts and other common eye diseases. And with progress in medical research increasingly driven by such techniques, the value of NHS data will only increase over time. It is a glistening prize for major health and pharmaceutical providers – or, indeed, big tech companies looking to move into the field.
That is why, as the leaked documents say, “obtaining commitments on the free flow of data is a top priority” for the US (you can find this on page 22). Free flows of data, including removing barriers to “data localisation”, imply that very sensitive health data could be taken and placed on servers outside of UK domestic law. And as Alan Winters, director of the Trade Policy Observatory at Sussex University has explained, combined with the US insistence that copyright and patent law are strictly enforced under a future trade deal, this could mean a situation where the UK is unable to analyse its health data without paying a royalty to Silicon Valley to use an algorithm.
Leaving the EU on the terms of the current withdrawal agreement – which imply a sharp break with the EU, including its various protections on data transfer – would leave t
Believe there is an RNS to drop.
As reported on the day on sharepad. Def Buy.
15:11:20-GMT GBX 26p 10,000 £2600.00 OB 25.5 26.0 Buy
15:11:51-GMT GBX 26p 23,076 £5999.76 OB 25.5 26.0 Buy
15:12:48-GMT GBX 25.5p 900 £229.50 OB 25.5 26.0 Sell
15:13:07-GMT GBX 25.95p 4,100 £1063.95 OB 25.5 26.0 Buy
15:15:15-GMT GBX 26.25p 1,000,000 £262500.00 OB 25.5 26.0 Unknown published 11/01/21
15:17:09-GMT GBX 25.99999p 25,721 £6687.457 OB 25.5 26.0 Unknown
15:25:53-GMT GBX 25.7155p 37,033 £9523.221 OB 25.5 26.0 Unknown
15:39:39-GMT GBX 25.7155p 10,000 £2571.55 OB 25.5 26.0 Unknown
15:44:38-GMT GBX 26p 3,827 £995.02 OB 25.5 26.0
So the MRHA approval on 14/12/2020 RNS does that only cover this one trial with Codagenix or does it cover all potential human challenge studies. If it is the same live attenuated virus we have developed, surely it is only a matter of time before more challenge studies are signed up. Or is there a seperate MRHA approval needed?
TOKYO (Reuters) - A new coronavirus variant has been detected in four travellers from Brazil's Amazonas state, Japan's Health Ministry said on Sunday, the latest new mutation of the virus discovered.
A ministry official said studies were underway into the efficacy of vaccines against the new variant, which differs from highly infectious variants first found in Britain and South Africa that have driven a surge in cases.
"At the moment, there is no proof showing the new variant found in those from Brazil is high in infectiousness," Takaji Wakita, head of the National Institute of Infectious Diseases, told a health ministry briefing.
Still, Brazil's Health Ministry said it has been notified by Japan's authorities that the new variant has 12 mutations, and one of them has already been identified also in the variants found in the United Kingdom and in South Africa. "It implies in a potential higher virus infectiousness," it said.
How much of this trials information could be used by a wearable company? How wider does it open that door?
One jab or two?
Just before Christmas the former prime minister, Mr Blair, writing in The Independent, called for an overhaul of the government’s vaccine strategy. He argued that in order to spread immunity more widely, those who had already been given their first jab should forego the second so that someone else might get their first.
From the moment this was proposed there was controversy. Once again, while politicians talk about following the science, the scientists are often at variance with one another. Professor Peter Openshaw of Imperial College, London said that Mr Blair’s proposal “made good sense”. But Professor Wendy Barclay, also of Imperial College, told MPs on the Science and Technology Committee that changing dosing would be “too risky”. Dr Simon Clarke of the University of Reading branded the proposal as “ridiculous”. The BMA expressed its opposition to one jab.
Hundreds of thousands of patients have now been informed that their second jabs are either cancelled or postponed indefinitely. There are medical precedents for this. The human papillomavirus vaccine which prevents cervical cancer was initially administered in three doses but was found to be so effective that it is now restricted to two.
Two doses of the Pfizer vaccine induce 95 percent immunity; the efficacy falls substantially with one dose. For the Oxford-AstraZeneca vaccine, the efficacy is 62 percent for two full doses but rises to 90 percent for those who are given a first half-dose and a second full dose.
The current consensus in the UK is that the two doses of the Oxford-AstraZeneca vaccine will now be administered between four and 12 weeks apart; but the Pfizer vaccine could be given as a single dose initially – despite the fact that it was authorised by the MHRA as a two-dose vaccine. According to a paper released by the MHRA this week, a longer gap between the first and second dose will confer a “stronger immune response”.
The Janssen (the Belgian subsidiary of Johnson & Johnson (NYSE:JNJ)) vaccine will be a single-shot vaccine which uses adenovirus and mRNA technology. It could be approved in the UK, Europe and the USA as early as next month. Watch this space.
Bottlenecks
Glass vials are in critically short supply across the globe. Last weekend, AstraZeneca had 15 million doses on hand waiting to be put into vials. Pascal Soriot, AstraZeneca’s CEO said the company could supply a million doses per week but that will rise to two million by mid-January. The Oxford vaccine needs to spend 20 days in a sterilisation process after manufacture before it can be used. Then each batch has to be checked by the NIBS.
As well as the 100 million doses of the Oxford vaccine ordered by the UK, the USA has ordered 300 million, the EU 400 million and Japan 120 million. Another 170 million have been earmarked for the Gavi alliance. At the current level of production, it will take years to deliver these orders.
PeterS23, just a though and happy for all comments. How much would PrepBio and Immutex cost us to buy and have complete control over to spin off. Are the monetization of these companies been hampered due to there split ownership? So effectively we are asking for a 3rd part to jump into bed with the company and oh yes stump up to take it forward?
John Henry, absolute toddle wash about price leaks. This share has risen over 20% since 18/12/2020. Was that all price leaking. No, it was not. There were a number of RNS postings. There was support just below 23p.
As a world leader, should Open orphan not be pushing for a Nasdaq listing on it's own?
As a world leader, should Open orphan not be pushing for a Nasdaq listing on it's own?
Those small II that may have sold, have had to sell to somebody....Oh yes those small PI have been buying, so the support the II gave the OO when it needed the £12million has been appreciated, they have made there money and now the PI are moaning...what do you want Bronxville?
Deepjoy, sounds like you got out of bed on the wrong side...I wonder what you call the price movement from Aug2016 till the beginning of 2019 if this is the longest down trend. Maybe you need to learn the art of technical analysis.
CF paying the recruits for doing a challenge study.